Other reports of navitoclax-resistant cancer cells induced in senescence by non-genotoxic chemotherapeutic agents such as alisertib or palbociclib [33] suggest that the DNA damage response may be important in reorganizing BCL-2 family factors into a navitoclax-sensitive BH3 network in senescent cancer cells. Here, BCL2 is linked to cancer.